A new highly purified human-derived FSH, Bravelle™, is as effective and well tolerated as recombinant follitropin beta in ovulation induction in infertile women with ovulatory dysfunction

Today's Therapeutic Trends

Volumn 19, Issue 4, 2001, Pages 297-313

  Feigenbaum, S L ^a   Miller, P ^a   Kaufmann, R ^a   Elkind Hirsch, K ^a   Fein, S H ^a   Marshall, D C ^a  

^a Ferring Pharmaceuticals Inc   (United States)

Author keywords

Bravelle; Follistim; Follitropin beta; Infertility; Ovulation induction; Polycystic ovarian syndrome; Pregnancy; Subcutaneous

Indexed keywords

FOLLITROPIN; LEUPRORELIN; RECOMBINANT FOLLITROPIN; UROFOLLITROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; FEMALE INFERTILITY; HEADACHE; HUMAN; INJECTION PAIN; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; MULTICENTER STUDY; NAUSEA; OVARY DISEASE; OVULATION INDUCTION; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; VAGINA BLEEDING;

EID: 0035191371     PISSN: 07412320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Clinical effects of human pituitary follicle stimulating hormone
2. Human menopausal gonadotropins
3. Clinical Review 100: Evaluation and treatment of the infertile couple
4. Induction of ovulation with gonadotrophins: hMG versus purified FSH
5. Purification and separation of follicle stimulating hormone (FSH) and luteinizing hormone (LH) from human postmenopausal gonadotropin (HMG). II. Preparation of biological apparently pure FSH by selective binding of the LH with an anti-HCG serum and subsequent chromatography
6. Ovulation induction in polycystic ovary syndrome: Effect of different menotropin preparations in regular and low dose regimens
7. Induction of ovulation in polycystic ovary: Human menopausal gonadotropin or human urinary follicle stimulating hormone?
8. Combined luteinizing hormone releasing hormone analogue and exogenous gonadotrophins for the treatment of infertility associated with polycystic ovaries
9. Human urinary follicle-stimulating hormone and human menopausal gonadotropin in induction of multiple follicle growth and ovulation
10. A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with Buserelin for superovulation and in vitro fertilization
11. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization
12. Similar pregnancy and spontaneous abortion rates after treatment with low-dose human menopausal gonadotropin versus pure follicle stimulating hormone in women with luteal phase defects
13. Comparison of urinary human follicle-stimulating hormone and human menopausal gonadotropins for ovarian stimulation in an in vitro fertilization program
14. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women
15. Comparison of the effects of HMG or pure FSH stimulation during suppression with an LHRH agonist analogue
16. Ovarian stimulation for in vitro fertilization and embryo transfer, human menopausal gonadotropin versus pure human follicle stimulating hormone: A randomized prospective study
17. Pharmacokinetics of natural/ recombinant FSH (follitropin) and some analogs
18. Developments in human recombinant follicle stimulating hormone technology: Are we going in the right direction?
19. Clinical pharmacology of recombinant human follicle stimulating hormone. II. Single doses and steady state pharmacokinetics
20. Circulating bioactive and immunoreactive recombinant human follicle stimulating hormone (Org 32489) after administration to gonadotropin-deficient subjects
21. In-vitro biopotency and glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), Metrodin and Metrodin-HP
22. A biological, immunological and physico-chemical comparison of the current clinical batches of the recombinant FSH preparations Gonal-F and Puregon
23. Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization
24. A randomized, open-label, parallel group, multi-center efficacy study comparing Ferring hFSH™ SC, Ferring hFSH™ IM and Follistim® SC in female patients undergoing in vitro fertilization
25. Recombinant human follicle stimulating hormone (r-hFSH; Gonal F) versus highly purified urinary FSH (Metrodin HP): Results of a randomized comparative study in women undergoing assisted reproductive techniques
26. Subcutaneously administered Repronex® in oligo-ovulatory female patients undergoing ovulation induction is as effective and well tolerated as intramuscular human menopausal gonadotropin treatment
27. Subcutaneously administered Repronex® in female patients undergoing in vitro fertilization is as effective and well tolerated as intramuscular menotropin treatment
28. Induction of ovulation in women undergoing assisted reproductive techniques: Recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP)
29. An open-label, parallel group, single center pharmacokinetic study in normal female subjects comparing Ferring hFSH™ SC and IM
30. Ovulation induction with recombinant human follicle-stimulating hormone and luteinizing hormone